ALX Oncology Inc.

9 clinical trials · Sponsor

Record	Firm	Date
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer (NCT07007559)	ALX Oncology Inc.	2025-12-10
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors (NCT07085091)	ALX Oncology Inc.	2025-08-18
A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07) (NCT05524545)	ALX Oncology Inc.	2022-11-02
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) (NCT05002127)	ALX Oncology Inc.	2022-01-15
Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04) (NCT04675333)	ALX Oncology Inc.	2021-05-10
A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05) (NCT04755244)	ALX Oncology Inc.	2021-05-05
Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) (NCT04675294)	ALX Oncology Inc.	2021-04-02
A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02) (NCT04417517)	ALX Oncology Inc.	2020-10-02

Every clearance here is in the API, with alerts when new ones post.